Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Gnter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A. A. Fox, Manesh R. Patel, ROCKET AF Investigators

    Research output: Contribution to journalLetter

    9 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)1001-1003
    Number of pages3
    JournalCirculation
    Volume135
    Issue number10
    DOIs
    Publication statusPublished - 7 Mar 2017

    Cite this

    Lindner, Samuel M. ; Fordyce, Christopher B. ; Hellkamp, Anne S. ; Lokhnygina, Yuliya ; Piccini, Jonathan P. ; Breithardt, Gnter ; Mahaffey, Kenneth W. ; Singer, Daniel E. ; Hacke, Werner ; Halperin, Jonathan L. ; Hankey, Graeme J. ; Berkowitz, Scott D. ; Nessel, Christopher C. ; Becker, Richard C. ; Fox, Keith A. A. ; Patel, Manesh R. ; ROCKET AF Investigators. / Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. In: Circulation. 2017 ; Vol. 135, No. 10. pp. 1001-1003.
    @article{de4674cd523046708d5f8aef8a238736,
    title = "Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis",
    keywords = "atrial fibrillation, renal function, SYSTEMIC EMBOLISM, OUTCOMES",
    author = "Lindner, {Samuel M.} and Fordyce, {Christopher B.} and Hellkamp, {Anne S.} and Yuliya Lokhnygina and Piccini, {Jonathan P.} and Gnter Breithardt and Mahaffey, {Kenneth W.} and Singer, {Daniel E.} and Werner Hacke and Halperin, {Jonathan L.} and Hankey, {Graeme J.} and Berkowitz, {Scott D.} and Nessel, {Christopher C.} and Becker, {Richard C.} and Fox, {Keith A. A.} and Patel, {Manesh R.} and {ROCKET AF Investigators}",
    year = "2017",
    month = "3",
    day = "7",
    doi = "10.1161/CIRCULATIONAHA.116.024666",
    language = "English",
    volume = "135",
    pages = "1001--1003",
    journal = "Circulation (Baltimore)",
    issn = "0009-7322",
    publisher = "Lippincott Williams & Wilkins",
    number = "10",

    }

    Lindner, SM, Fordyce, CB, Hellkamp, AS, Lokhnygina, Y, Piccini, JP, Breithardt, G, Mahaffey, KW, Singer, DE, Hacke, W, Halperin, JL, Hankey, GJ, Berkowitz, SD, Nessel, CC, Becker, RC, Fox, KAA, Patel, MR & ROCKET AF Investigators 2017, 'Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis' Circulation, vol. 135, no. 10, pp. 1001-1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666

    Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. / Lindner, Samuel M.; Fordyce, Christopher B.; Hellkamp, Anne S.; Lokhnygina, Yuliya; Piccini, Jonathan P.; Breithardt, Gnter; Mahaffey, Kenneth W.; Singer, Daniel E.; Hacke, Werner; Halperin, Jonathan L.; Hankey, Graeme J.; Berkowitz, Scott D.; Nessel, Christopher C.; Becker, Richard C.; Fox, Keith A. A.; Patel, Manesh R.; ROCKET AF Investigators.

    In: Circulation, Vol. 135, No. 10, 07.03.2017, p. 1001-1003.

    Research output: Contribution to journalLetter

    TY - JOUR

    T1 - Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

    AU - Lindner, Samuel M.

    AU - Fordyce, Christopher B.

    AU - Hellkamp, Anne S.

    AU - Lokhnygina, Yuliya

    AU - Piccini, Jonathan P.

    AU - Breithardt, Gnter

    AU - Mahaffey, Kenneth W.

    AU - Singer, Daniel E.

    AU - Hacke, Werner

    AU - Halperin, Jonathan L.

    AU - Hankey, Graeme J.

    AU - Berkowitz, Scott D.

    AU - Nessel, Christopher C.

    AU - Becker, Richard C.

    AU - Fox, Keith A. A.

    AU - Patel, Manesh R.

    AU - ROCKET AF Investigators

    PY - 2017/3/7

    Y1 - 2017/3/7

    KW - atrial fibrillation

    KW - renal function

    KW - SYSTEMIC EMBOLISM

    KW - OUTCOMES

    U2 - 10.1161/CIRCULATIONAHA.116.024666

    DO - 10.1161/CIRCULATIONAHA.116.024666

    M3 - Letter

    VL - 135

    SP - 1001

    EP - 1003

    JO - Circulation (Baltimore)

    JF - Circulation (Baltimore)

    SN - 0009-7322

    IS - 10

    ER -